![](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/21175973-726984434-ad-24560-100x64.jpeg)
Hong Kong approves Eisai's Leqembi for treatment of Alzheimer’s Disease
Leqembi’s approval in Hong Kong is based on the large global Phase 3 Clarity AD study Eisai Co. and Biogen Inc. have announced that the Department of Health in Hong Kong has approved humanised anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody …